why choose us

300×250 Ad Slot

Drug FDA Status

Showing 170 of 185 result(s) (Page 17 of 19)
Drug Name: Rystiggo

Active Ingredient: rozanolixizumab-noli

Approval Date: 2023-06-26

Description: To treat generalized myasthenia gravis in adults who are anti-acetylcholine receptor- or anti-muscle-specific tyrosine kinase antibody-positive

Drug Name: Litfulo

Active Ingredient: ritlecitinib

Approval Date: 2023-06-23

Description: To treat severely patchy hair loss
Drug Trials Snapshot

Drug Name: Columvi

Active Ingredient: glofitamab-gxbm

Approval Date: 2023-06-15

Description: To treat diffuse large B-cell lymphoma, not otherwise specified, or large B-cell lymphoma arising from follicular lymphoma after two or more lines of systemic therapy
Drug Trials Snapshot

Drug Name: Inpefa

Active Ingredient: sotagliflozin

Approval Date: 2023-05-26

Description:

?To treat heart failure 

Drug Name: Posluma

Active Ingredient: flotufolastat F 18

Approval Date: 2023-05-25

Description: To use with positron emission tomography imaging in certain patients with prostate cancer
Drug Trials Snapshot

Drug Name: Paxlovid

Active Ingredient: nirmatrelvir, ritonavir

Approval Date: 2023-05-25

Description: To treat mild-to-moderate COVID-19 in adults at high risk for progression to severe COVID-19
Press Release
Drug Trials Snapshot

Drug Name: Xacduro

Active Ingredient: sulbactam, durlobactam

Approval Date: 2023-05-23

Description:

To treat hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex
Press Release

Drug Name: Epkinly

Active Ingredient: epcoritamab-bysp

Approval Date: 2023-05-19

Description: To treat relapsed or refractory diffuse large B-cell lymphoma (not otherwise specified) and high-grade B-cell lymphoma after two or more lines of systemic therapy

Drug Name: Miebo

Active Ingredient: perfluorhexyloctane

Approval Date: 2023-05-18

Description: To treat signs and symptoms of dry eye disease

Drug Name: Veozah

Active Ingredient: fezolinetant

Approval Date: 2023-05-12

Description: To treat moderate to severe hot flashes caused by menopause
Press Release

300×250 Ad Slot